Australian (ASX) Stock Market Forum

SPL - Starpharma Holdings

Jump to new
Pants dropper announcement out today. SP approx.-30% down as US FDA requires confirmatory clinical data prior to approval.
https://www.asx.com.au/asxpdf/20181227/pdf/441jx9s15nls7l.pdf

I think this might be an opportunity to put the products' potential beyond doubt and provide further exposure and acknowledgement of dendrimers to the FDA. I might top up a little while the price is reeling.
 
I agree but be careful in this bear market. Note selling from substantial holder.
I am now 25% cash.
 
NO! NO! NOOOOO!!
You are supposed to have a 23.44% recovery NEXT YEAR in 2019, because that's when the 2019 ASF comp starts, not on the last day this year.
Bloody hell. You stagnate from here on, then just you watch out.
 
jbocker said:
NO! NO! NOOOOO!!
You are supposed to have a 23.44% recovery NEXT YEAR in 2019, because that's when the 2019 ASF comp starts, not on the last day this year.
Bloody hell. You stagnate from here on, then just you watch out.
Click to expand...
Can't keep a good company down.
 
Just bought some more at $1.07. It was always going to come back after such a sharp rise.
Decided to put my money where my mouth is and seriously back the company. I don't think it will drop below $1.03 but who knows?
 
Market seemed to like the spiel handed out yesterday.
https://www.asx.com.au/asxpdf/20190403/pdf/4440lqtxcsy6r7.pdf
Nothing terribly different other than I note the following mentioned..
FDA meeting in April to discuss confirmatory clinical data required prior to approval of VivaGel® BV in the US.
Hopefully this will prove up Vivagel claims to the FDA, and then recover the drop in SP when FDA requested further data last Xmas.
 
jbocker said:
Market seemed to like the spiel handed out yesterday.
https://www.asx.com.au/asxpdf/20190403/pdf/4440lqtxcsy6r7.pdf
Nothing terribly different other than I note the following mentioned..
FDA meeting in April to discuss confirmatory clinical data required prior to approval of VivaGel® BV in the US.
Hopefully this will prove up Vivagel claims to the FDA, and then recover the drop in SP when FDA requested further data last Xmas.
Click to expand...

Yes, I was thinking about putting it on the bottom thread. Quite smooth parabola.
 
jbocker said:
Market seemed to like the spiel handed out yesterday.
https://www.asx.com.au/asxpdf/20190403/pdf/4440lqtxcsy6r7.pdf
Nothing terribly different other than I note the following mentioned..
FDA meeting in April to discuss confirmatory clinical data required prior to approval of VivaGel® BV in the US.
Hopefully this will prove up Vivagel claims to the FDA, and then recover the drop in SP when FDA requested further data last Xmas.
Click to expand...
Also launch of Vivagel in Australia later this month.
 
I'm on my way from misery to happiness today (uh-huh, uh-huh, uh-huh, uh-huh)
I'm on my way from misery to happiness today (yea, yea, yea, yea)
I'm on my way to what I want from this world


Melbourne, Australia; 16 April 2019: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VivaGel® BV has been officially launched in Australia by Aspen Pharmacare (Aspen) as Fleurstat BVgel. The product has undergone distribution across Australia and is already available in some pharmacies. It will be progressively rolled-out nationally over the coming weeks. This is the first launch of VivaGel® BV in the world and further launches by Mundipharma are expected in Europe in May/June this year.

VivaGel® BV (Fleurstat BVgel) is a novel, non-antibiotic therapy for treatment of bacterial vaginosis (BV) and relief of symptoms. BV is the most common vaginal condition worldwide and twice as common as thrush. VivaGel® BV (Fleurstat BVgel) is an Australian innovation – invented, fully developed and taken through to commercialisation by Starpharma.

BV is a troublesome and often recurrent condition that causes unpleasant vaginal odour and discharge symptoms that have significant social impacts for women. BV has also been associated with a range of other serious reproductive health-related medical problems. Until now, women have only been able to access antibiotic-based treatments for BV, which are only available by prescription from a GP or specialist.

Fleurstat BVgel is a non-antibiotic therapy and is the only BV treatment available over-the- counter (OTC) at pharmacies, without the need for a prescription. Fleurstat BVgel is being marketed in Australia by Aspen.
 
.
Knobby22 said:
I'm on my way from misery to happiness today (uh-huh, uh-huh, uh-huh, uh-huh)
I'm on my way from misery to happiness today (yea, yea, yea, yea)
I'm on my way to what I want from this world
Click to expand...

I imagine quite a few ladies may well start singing along with you Knobby uh-huh, uh-huh, uh-huh, uh-huh..
Go Starpharma!
 
Good to see some continuing support this morning. The BV product has been conceptualised and developed IN Australia. Should be MORE OF IT!!! Great to see it now marketed in Australia first and then onto Europe and hopefully rest of the world.
Hope that goes well, and that the dendrimer research and development continues successfully in cancer treatments and other possibilities.
 
Very good news, don't forget it is a model probably based on mice.
Combined with the rollout of Vivagel though the world the future could be very good. If only the USA weren't being so hard assed slowing down the roll out in the country with the most problems.

DEP® irinotecan combination outperforms in refractory human colon cancer model

· DEP® irinotecan, a proprietary nanoparticle formulation, in combination with cetuximab (Erbitux®) showed complete suppression of tumour growth and 100% survival in an irinotecan-refractory human colon cancer model

· The significant antitumor effect induced by DEP® irinotecan was despite the fact that leading colon cancer treatments, irinotecan (Camptosar®) and Erbitux®, showed limited activity in this human colon cancer model

· This study builds on previously announced promising efficacy data for

DEP® irinotecan in human colon and pancreatic cancer models

· Starpharma is currently completing final trial preparations for the DEP® irinotecan phase 1/2 trial expected to start mid-year
 
Starpharma has built a really close relationship with AstroZeneca, now getting involved with their oncology drug also.

AstraZeneca Has Option to Licence DEP Oncology Drug Candidate for Option Exercise Fee of $5M
 
The low Australian Dollar is good for StarPharma as they manufacture here.
I just hope that they are getting traction overseas with the green whistle product.
 
Knobby22 said:
The low Australian Dollar is good for StarPharma as they manufacture here.
I just hope that they are getting traction overseas with the green whistle product.
Click to expand...
Green Whistle? is that theirs, first I have heard of it.
 

Similar threads

System
TRP - Tissue Repair
Replies
3
Views
1K
Dona Ferentes
Dona Ferentes
M
IMMU - Immunicum AB (NASDAQ)
Replies
19
Views
7K
maquet
M
shares
MCM - MC Mining
2 3 4
Replies
67
Views
25K
Dona Ferentes
Dona Ferentes
Gurgler
CYT - Cytopia Limited
Replies
1
Views
4K
moneymajix
moneymajix
O
INEX Pharmaceuticals: Great licensing agreement with Hana Biosciences
Replies
3
Views
5K
ollinbg
O
Top